Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
Phase of Trial: Phase IV
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 12 Sep 2018 Planned number of patients changed from 437 to 1990.
- 31 May 2018 Planned number of patients changed from 1500 to 437.